27-Year-Old Man Presents With an Anterior Mediastinal Mass

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

The combination of nurulimab plus prolgolimab enhanced PFS, ORR, and DCR compared with prolgolimab monotherapy in unresectable or metastatic melanoma.

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

William R. Kennedy, MD

Same-Day G-CSF After Chemo Appears Safe, Efficacious in Breast Cancer

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.

Roman Fabbricatore

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

Health Care Professional Research Highlights Barriers to Clinical Trial Diversity

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Tim Cortese

Radical Prostatectomy Linked to Lower GU Toxicity in Localized Prostate Cancer

Nurulimab/Prolgolimab Yield Superior Efficacy in Advanced Melanoma

Toxicity complications were assessed between single- and multiple-treatment modalities for patients with localized prostate cancer.

Related Content

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

The combination of nurulimab plus prolgolimab enhanced PFS, ORR, and DCR compared with prolgolimab monotherapy in unresectable or metastatic melanoma.

William R. Kennedy, MD

Same-Day G-CSF After Chemo Appears Safe, Efficacious in Breast Cancer

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Roman Fabbricatore

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

Health Care Professional Research Highlights Barriers to Clinical Trial Diversity

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Tim Cortese

Radical Prostatectomy Linked to Lower GU Toxicity in Localized Prostate Cancer